Mereo BioPharma Group plc
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab, an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for use in the treatment of tumors. The company is also developing Navi… Read more
Mereo BioPharma Group plc (MAH0) - Net Assets
Latest net assets as of September 2025: €46.60 Million EUR
Based on the latest financial reports, Mereo BioPharma Group plc (MAH0) has net assets worth €46.60 Million EUR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€53.60 Million) and total liabilities (€7.00 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €46.60 Million |
| % of Total Assets | 86.93% |
| Annual Growth Rate | -3.23% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 49.81 |
Mereo BioPharma Group plc - Net Assets Trend (2016–2024)
This chart illustrates how Mereo BioPharma Group plc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Mereo BioPharma Group plc (2016–2024)
The table below shows the annual net assets of Mereo BioPharma Group plc from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €60.97 Million | +20.64% |
| 2023-12-31 | €50.54 Million | -18.31% |
| 2022-12-31 | €61.87 Million | -29.70% |
| 2021-12-31 | €88.00 Million | +687.82% |
| 2020-12-31 | €-14.97 Million | -137.19% |
| 2019-12-31 | €40.26 Million | +22.84% |
| 2018-12-31 | €32.77 Million | -47.55% |
| 2017-12-31 | €62.48 Million | -21.16% |
| 2016-12-31 | €79.26 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Mereo BioPharma Group plc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 42230375900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €523.85 Million | 859.21% |
| Total Equity | €60.97 Million | 100.00% |
Mereo BioPharma Group plc Competitors by Market Cap
The table below lists competitors of Mereo BioPharma Group plc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Northern Ocean Ltd
PINK:NTNOF
|
$57.52 Million |
|
Financeira Alfa S.A. - Crédito Financiamento e Investimentos
SA:CRIV3
|
$57.54 Million |
|
Pacific Petroleum Transportation JSC
VN:PVP
|
$57.55 Million |
|
OXFORD METRICS LS-0025
F:RNI
|
$57.58 Million |
|
Cheng Fwa Industrial Ltd
TWO:5426
|
$57.46 Million |
|
1895 of Wisconsin Inc Bancorp
NASDAQ:BCOW
|
$57.43 Million |
|
Emvision Medical Devices Ltd
AU:EMV
|
$57.37 Million |
|
River Valley Community Bancorp
PINK:RVCB
|
$57.37 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Mereo BioPharma Group plc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 50,537,000 to 60,969,000, a change of 10,432,000 (20.6%).
- Net loss of 43,253,000 reduced equity.
- New share issuances of 47,000,000 increased equity.
- Other factors increased equity by 6,685,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-43.25 Million | -70.94% |
| Share Issuances | €47.00 Million | +77.09% |
| Other Changes | €6.68 Million | +10.96% |
| Total Change | €- | 20.64% |
Book Value vs Market Value Analysis
This analysis compares Mereo BioPharma Group plc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.29x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.38x to 4.29x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €0.88 | €0.34 | x |
| 2018-12-31 | €0.46 | €0.34 | x |
| 2019-12-31 | €0.41 | €0.34 | x |
| 2020-12-31 | €-0.04 | €0.34 | x |
| 2021-12-31 | €0.15 | €0.34 | x |
| 2022-12-31 | €0.10 | €0.34 | x |
| 2023-12-31 | €0.07 | €0.34 | x |
| 2024-12-31 | €0.08 | €0.34 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Mereo BioPharma Group plc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -70.94%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.25x
- Recent ROE (-70.94%) is below the historical average (-50.25%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -35.82% | 0.00% | 0.00x | 1.09x | €-36.32 Million |
| 2017 | -62.09% | 0.00% | 0.00x | 1.54x | €-45.05 Million |
| 2018 | -97.74% | 0.00% | 0.00x | 2.05x | €-35.31 Million |
| 2019 | -86.56% | 0.00% | 0.00x | 2.15x | €-38.87 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | €-162.13 Million |
| 2021 | 14.46% | 34.90% | 0.29x | 1.44x | €3.92 Million |
| 2022 | -55.27% | 0.00% | 0.00x | 1.42x | €-40.38 Million |
| 2023 | -58.31% | -294.66% | 0.15x | 1.32x | €-34.52 Million |
| 2024 | -70.94% | 0.00% | 0.00x | 1.25x | €-49.35 Million |
Industry Comparison
This section compares Mereo BioPharma Group plc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Mereo BioPharma Group plc (MAH0) | €46.60 Million | -35.82% | 0.15x | $57.50 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |